Macrogen Valuation
Is A038290 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A038290 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A038290 (₩20300) is trading below our estimate of fair value (₩51381.95)
Significantly Below Fair Value: A038290 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A038290?
Other financial metrics that can be useful for relative valuation.
What is A038290's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₩202.57b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.7x |
Enterprise Value/EBITDA | 21.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A038290's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 9.9x | ||
A220100 FutureChemLtd | 20.9x | n/a | ₩291.2b |
A268600 Cellivery Therapeutics | 10.9x | n/a | ₩244.9b |
A278650 HLB bioStepLtd | 6.1x | n/a | ₩322.0b |
A359090 C&R Research | 1.9x | n/a | ₩103.3b |
A038290 Macrogen | 1.5x | 10.8% | ₩202.6b |
Price-To-Sales vs Peers: A038290 is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (9.6x).
Price to Earnings Ratio vs Industry
How does A038290's PE Ratio compare vs other companies in the KR Life Sciences Industry?
Price-To-Sales vs Industry: A038290 is good value based on its Price-To-Sales Ratio (1.5x) compared to the KR Life Sciences industry average (4.5x).
Price to Sales Ratio vs Fair Ratio
What is A038290's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1.5x |
Fair PS Ratio | 2x |
Price-To-Sales vs Fair Ratio: A038290 is good value based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.